Skip to main content
. Author manuscript; available in PMC: 2010 Nov 23.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2006 Nov 16;27(2):422–429. doi: 10.1161/01.ATV.0000252826.96134.21

Figure 4.

Figure 4

Novel synergy between CRP and thrombin involves Src kinases and secondary mediators. A and B, Human platelets were aggregated with thrombin (0.015 to 0.02U/mL), CRP (0.5 to 1.5 µg/mL), thrombin/CRP in combination, in the absence or presence of PP2 (10 µmol/L) and/or ARC66931MX (10 µmol/L), MRS2176 (100 µmol/L), and indomethacin (10 µmol/L). Platelet aggregation was plotted as the maximal extent of aggregation. C, Washed human platelets were treated with DMSO (black bars), PP2 (gray bars), or ARC69931MX, MRS2176, Indomethacin, and PP2 (AMIP) (white bars) before stimulation with thrombin (0.04U/mL), CRP (2.0 µg/mL), or CRP/thrombin (2.0 µg/mL and 0.04U/mL, respectively). Platelets bound OG-FGN for 5 minutes before samples were read using FL1. Results are arbitrary units (mean±SEM), n=3; *P<0.05; ***P<0.001.